Literature DB >> 3335030

In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.

R G Steen1, R J Tamargo, K A McGovern, S S Rajan, H Brem, J P Wehrle, J D Glickson.   

Abstract

In vivo 31P nuclear magnetic resonance spectroscopy was used to examine the bioenergetics of the rat 9L gliosarcoma during untreated growth and in response to chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Tumor growth was associated with a decline in the phosphocreatine and nucleoside triphosphate resonances, consistent with an increase in tumor hypoxia during untreated growth. Following chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea (10 mg/kg), tumor levels of phosphocreatine and nucleoside triphosphate rebounded while the level of inorganic phosphate in the tumor declined. Histological comparison of treated and untreated tumor sections 4 days posttreatment showed that the treated tumor had a lower proportion of necrotic cells, a higher proportion of viable cells, and a 5-fold higher level of interstitial space than the control tumor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335030

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance.

Authors:  J M Rozental; R L Levine; R J Nickles
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130

2.  In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T.

Authors:  Victor D Schepkin; Fabian Calixto Bejarano; Thomas Morgan; Shannon Gower-Winter; Manuel Ozambela; Cathy W Levenson
Journal:  Magn Reson Med       Date:  2011-07-11       Impact factor: 4.668

Review 3.  In Vivo Molecular Electron Paramagnetic Resonance-Based Spectroscopy and Imaging of Tumor Microenvironment and Redox Using Functional Paramagnetic Probes.

Authors:  Valery V Khramtsov
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

4.  Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Authors:  Elke Hattingen; Alina Jurcoane; Oliver Bähr; Johannes Rieger; Jörg Magerkurth; Sandra Anti; Joachim P Steinbach; Ulrich Pilatus
Journal:  Neuro Oncol       Date:  2011-09-02       Impact factor: 12.300

5.  Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.

Authors:  S J Tapscott; A D Miller; J M Olson; M S Berger; M Groudine; A M Spence
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.

Authors:  R G Steen; K Kitagishi; K Morgan
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.

Authors:  J M Rozental; J D Cohen; M P Mehta; R L Levine; J M Hanson; R J Nickles
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

8.  Relationship of perfusion to edema in the 9L gliosarcoma.

Authors:  R G Steen; S Kromhout-Schiro; M M Graham
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

Review 9.  Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research.

Authors:  R D Fross; P C Warnke; D R Groothuis
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

10.  Early estrogen-induced metabolic changes and their inhibition by actinomycin D and cycloheximide in human breast cancer cells: 31P and 13C NMR studies.

Authors:  M Neeman; H Degani
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.